Danaher | DHR - Current Liabilities


Danaher reported $9.05B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Abbott USD 16.15B 1.66B Sep/2026
Agilent USD 2.29B 20M Jun/2026
Align Technology USD 1.91B 4.9M Sep/2026
Becton, Dickinson and Co. USD 9.54B 139M Sep/2026
Bio Techne USD 361.27M 197.57M Sep/2026
Bio-Rad Laboratories USD 969.1M 7.8M Sep/2026
Boston Scientific USD 5.98B 446M Sep/2026
Bruker USD 1.17B 32.6M Sep/2026
Charles River Laboratories USD 1.09B 45.49M Sep/2026
Danaher USD 9.05B 945M Sep/2026
Dentsply International USD 1.22B 32M Sep/2026
Edwards Lifesciences USD 1.58B 68.8M Sep/2026
ESCO Technologies USD 546.69M 46.33M Jun/2026
Fortive USD 1.29B 800K Sep/2026
Henry Schein USD 3.6B 110M Sep/2026
Illumina USD 1.16B 422M Sep/2026
Intuitive Surgical USD 3.23B 652.4M Sep/2026
IQVIA Holdings USD 7.78B 1.04B Sep/2026
Keysight Technologies USD 2.61B 37M Jun/2026
Laboratory Of America USD 2.82B 695M Sep/2026
Medtronic USD 11.8B 141M Jun/2026
Mettler Toledo International USD 1.25B 49.81M Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
OraSure Technologies USD 25.12M 18.96M Jun/2026
Quest Diagnostics USD 1.83B 46M Sep/2026
Quidel USD 1.07B 73.7M Sep/2026
Repligen USD 125.69M 6.97M Sep/2026
Revvity USD 701.48M 574.88M Sep/2026
Roper Industries USD 4.57B 1.1B Sep/2026
Stryker USD 6.5B 184M Sep/2026
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Waters USD 2.4B 126M Jun/2026
Zimmer Biomet Holdings USD 3.5B 488.9M Sep/2026